NALOXONE HYDROCHLORIDE INJECTION DIN 02572214
Status: Approved
Holder: JUNO PHARMA CANADA INC.
Health Canada record
| Active ingredient(s) | NALOXONE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.4 MG |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous; Intravenous; Intramuscular |
| Schedule | ETHICAL |
| Class | Human |
| ATC | V03AB15 NALOXONE |
| Original market date | |
| Current status date | 09-Oct-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Juno Pharma Canada Inc. — licence 3-002916, currently licensed, last inspection rating C (2025-11-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NALOXONE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE DIHYDRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02455935 | INJECTABLE NALOXONE HYDROCHLORIDE | OMEGA LABORATORIES LIMITED | Solution | NALOXONE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.4 MG | Marketed |
| 02464357 | INJECTABLE NALOXONE HYDROCHLORIDE | OMEGA LABORATORIES LIMITED | Solution | NALOXONE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE DIHYDRATE) 1 MG | Approved |
| 02393034 | NALOXONE HYDROCHLORIDE INJECTION | OMEGA LABORATORIES LIMITED | Solution | NALOXONE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.4 MG | Marketed |
| 02393042 | NALOXONE HYDROCHLORIDE INJECTION | OMEGA LABORATORIES LIMITED | Solution | NALOXONE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE DIHYDRATE) 1 MG | Marketed |
| 02382482 | NALOXONE HYDROCHLORIDE INJECTION USP | HIKMA CANADA LIMITED | Solution | NALOXONE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.4 MG | Marketed |
| 02459892 | NALOXONE HYDROCHLORIDE INJECTION, USP | STRIDES PHARMA CANADA INC | Solution | NALOXONE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.4 MG | Approved |
| 02382601 | NALOXONE HYDROCHLORIDE INJECTION SDZ PRESERVATIVE FREE | SANDOZ CANADA INCORPORATED | Solution | NALOXONE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.4 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 38439 | 2026-10-09 | Abbreviated New Drug Submission (ANDS) |